MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PERT Consortium and BTG Form Strategic Partnership - BTG plc announced a strategic partnership with the PERT Consortium™ to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERT™ programs across the U.S - PERTConsortium.org / BTGplc.com
PERT Consortium and BTG Form Strategic Partnership

 

NewswireToday - /newswire/ - Bothell, WA, United States, 2018/06/21 - BTG plc announced a strategic partnership with the PERT Consortium™ to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERT™ programs across the U.S - PERTConsortium.org / BTGplc.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc, the global healthcare company, today announced at the annual PERT Consortium™ Meeting in Nashville, TN, a strategic partnership with the PERT Consortium™ to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERT™ programs across the U.S.

In the United States, pulmonary embolism afflicts 500,000 600,000 patients annually1,2 and is either a primary or secondary cause of death in 150,000 200,000 of these individuals2. In their new partnership, BTG and the PERT Consortium™ are uniting to address this disease via expanding options for professional education, expanding clinical research, establishing quality benchmarks for care of PE, and developing new mobile technologies to convene PERT teams and improve decision-making.

“With this partnership, we are reaffirming our long-standing commitment to improving patient care and reducing in-hospital mortality associated with Pulmonary Embolism,” said BTG Chief Medical Officer, Francis Facchini. “By partnering with the PERT Consortium™, we hope to develop new strategies to transform the PE treatment paradigm.”

“We applaud BTG’s commitment to research and their leadership in the field of PE,” said PERT Consortium™ President, Victor Tapson. “This partnership will expand the body of clinical evidence and improve multi-disciplinary decision-making for PE patients.”

“PE is a pervasive disease that is under-recognized and undertreated,” according to Consortium Immediate Past-president Kenneth Rosenfield. “Our collaboration with BTG will enable the PERT Consortium™ to increase provider and patient awareness about PE, and establish new benchmarks for high quality care of the patient with this disease.”

About Pulmonary Embolism
Pulmonary Embolism (PE) is a condition that occurs when a piece of a blood clot breaks off from a clot in the legs and travels through the vasculature -- getting trapped in the Pulmonary Arteries. When this happens, the clot blocks blood from getting to some areas of the lungs to receive oxygen. This may lead to excessive strain on the right side of the heart, ultimately leading to heart failure and/or cardiovascular collapse. PEs can be immediately fatal, but if diagnosed and appropriate therapy started, mortality can be reduced from approximately 30 percent to less than 10 percent.

About Pulmonary Embolism Response Teams (PERT)
The first PERT™ was created by a multi-disciplinary team of physicians at Massachusetts General Hospital (MGH) in 2012. Their intent was to develop the necessary clinical, educational, and research infrastructure for the advancement of PE care. Since then, the PERT™ multidisciplinary approach has allowed for the streamlined evaluation of patients, formulation of comprehensive treatment plans and the rapid mobilization of resources to provide the highest level of care to those in need. The PERT™ model has since grown in popularity and continues to be adopted by institutions across the US and beyond.

About the PERT Consortium
The PERT Consortium™ (pertconsortium.org) is a not-for-profit 501c3 organization, whose mission is to serve the general public by undertaking activities to advance the status of PE care and promote research, enhance quality, and optimize outcome in the treatment of pulmonary embolism. Specifically, the Consortium intends to: 1) Promote the adoption of the PERT model in healthcare institutions across the United States to ensure the prompt diagnosis and high quality treatment of pulmonary embolism; 2) Expand the current body of scientific literature on the diagnosis and treatment of pulmonary embolism through the funding of scientific endeavors; 3) Educate the general public and healthcare professionals regarding pulmonary embolism diagnosis, treatment, and care.

About BTG
BTG (btgplc.com) is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. BTG’s Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins.

Reference materials as the remarks in the press release:

1. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. US Department of Health and Human Services report, 2008.
2. Ansari A. Acute and chronic pulmonary thromboembolism: current perspectives. I. Glossary of terms, historic evolution and prevalence. Clinical Cardiology(1986), 9:398-402

Contacts
Andy Burrows, VP Corporate & Investor Relations - BTG
P: +44(0)20 7575 1741 / M: +44(0)79 9053 0605

Stuart Hunt, Investor Relations Manager - BTG
P: +44(0)20 7575 1582 / M: +44(0)78 1577 8536

Chris Gale, Vice President - Greentarget Communications
P: +1 646-695-2883 / M: +1 203-570-4681

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


PERT Consortium and BTG Form Strategic Partnership

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)77 7325 1178 (mobile) chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®
DSM and Industry Partners Launch Coalition to Close the Loop on Dyneema® - The World’s Strongest Fiber™
Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®
Tergus Lauded by Frost & Sullivan for its Full-spectrum CRO Services for Therapeutics in Dermatology
Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with its Differentiated Molecular Laboratory Information Management System
DSM Launches Three Times Faster-acting Form of Vitamin D Supplement in Australia to Support Immune Health
Ipsen Announces New Data from the Phase II CLARINET FORTE Study
South Carolina-based IMCS Awarded Major NIH Research Grant
Preventive Healthcare Measures to Combat Obesity and Lifestyle Diseases Steer Demand for Nutritional Lipids Globally Finds Frost & Sullivan
Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for its Unmatched Breadth of Services to Support Clinical Trials
Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product, Prenylium®
Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Limelon Advertising, Co.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)